These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 307580)
1. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. Brodt P; Gordon J J Immunol; 1978 Jul; 121(1):359-62. PubMed ID: 307580 [TBL] [Abstract][Full Text] [Related]
2. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. Sacks DL; Scott PA; Asofsky R; Sher FA J Immunol; 1984 Apr; 132(4):2072-7. PubMed ID: 6230400 [TBL] [Abstract][Full Text] [Related]
3. Regulation of lymphocyte production in the bone marrow. I. Turnover of small lymphocytes in mice depleted of B lymphocytes by treatment with anti-IgM antibodies. Fulop G; Gordon J; Osmond DG J Immunol; 1983 Feb; 130(2):644-8. PubMed ID: 6600249 [TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity. Ciavarra RP; Vitetta ES; Forman J J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362 [TBL] [Abstract][Full Text] [Related]
5. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859 [TBL] [Abstract][Full Text] [Related]
6. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice. Cerny A; Starobinski M; Hügin AW; Sutter S; Zinkernagel RM; Izui S J Immunol; 1987 Jun; 138(12):4222-8. PubMed ID: 3495583 [TBL] [Abstract][Full Text] [Related]
7. Ocular herpes simplex virus infection is diminished by depletion of B lymphocytes. Jordan C; Baron S; Dianzani F; Barber J; Stanton GJ J Immunol; 1983 Sep; 131(3):1554-7. PubMed ID: 6411818 [TBL] [Abstract][Full Text] [Related]
8. Suppression of follicular trapping of antigen-antibody complexes in mice treated with anti-IgM or anti-IgD antibodies from birth. Enriquez-Rincon F; Andrew E; Parkhouse RM; Klaus GG Immunology; 1984 Dec; 53(4):713-9. PubMed ID: 6389323 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM. Perek Y; Hurwitz E; Burowski D; Haimovich J J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103 [TBL] [Abstract][Full Text] [Related]
10. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo. Yoshioka T; Sato S; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429 [TBL] [Abstract][Full Text] [Related]
11. Changes in the host lymphocyte subsets during chemical carcinogenesis. Brodt P; Lala PK Cancer Res; 1983 Sep; 43(9):4315-22. PubMed ID: 6871866 [TBL] [Abstract][Full Text] [Related]
12. Proliferative response to anti-IgM antibodies of various B lymphocyte subpopulations isolated by cell sorting. Sidman CL; Unanue ER J Immunol; 1978 Dec; 121(6):2129-36. PubMed ID: 309893 [TBL] [Abstract][Full Text] [Related]
13. Effects of neonatal anti-delta antibody treatment on the murine immune system. I. Suppression of development of surface IgD+ B cells and expansion of a surface IgM+ IgD- B lymphocyte population. Finkelman FD; Mond JJ; Metcalf ES J Immunol; 1983 Aug; 131(2):593-600. PubMed ID: 6602840 [TBL] [Abstract][Full Text] [Related]
14. Chronic Giardia muris infection in anti-IgM-treated mice. I. Analysis of immunoglobulin and parasite-specific antibody in normal and immunoglobulin-deficient animals. Snider DP; Gordon J; McDermott MR; Underdown BJ J Immunol; 1985 Jun; 134(6):4153-62. PubMed ID: 3872910 [TBL] [Abstract][Full Text] [Related]
16. B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis. Scott P; Natovitz P; Sher A J Immunol; 1986 Aug; 137(3):1017-21. PubMed ID: 3487581 [TBL] [Abstract][Full Text] [Related]
17. Serum-mediated suppression of nonspecific B cell activation. II. Relative resistance of B cells from the NZB mouse strain to regulation by a natural inhibitor in normal mouse serum. Walker SM; Sturtevant JE; Weigle WO J Immunol; 1981 Sep; 127(3):1204-7. PubMed ID: 6973581 [TBL] [Abstract][Full Text] [Related]
18. Polyclonal activation of the murine immune system by an antibody to IgD. IV. In vivo activation of B lymphocytes from immune defective CBA/N mice. Muul LM; Scher I; Mond JJ; Finkelman FD J Immunol; 1983 Nov; 131(5):2226-31. PubMed ID: 6605378 [TBL] [Abstract][Full Text] [Related]
19. T cell development in B cell deficient mice. III. Restriction specificity of suppressor T cell factor(s) produced in mice treated chronically with rabbit anti-mouse mu chain antibody. HayGlass KT; Naides SJ; Benacerraf B; Sy MS J Mol Cell Immunol; 1985; 2(2):107-17. PubMed ID: 2978459 [TBL] [Abstract][Full Text] [Related]
20. Tumor-specific immune responsiveness of the tumor-bearing host. Burk MW; Yu S; McKhann CF Isr J Med Sci; 1976; 12(4-5):360-8. PubMed ID: 939694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]